Deep Dive: The Gold Rush to Cure the Obesity ...

Up next

Nvidia Is Cheapest It’s Been Since 2019, Meta Tests New ‘Super’ Glasses

Market update for July 9, 2026.Check out the Public app for incredible investing tools and to support the show (LINK)Follow us on Instagram (@TheRundownDaily) for bonus content and instant reactions.In today’s episode, Zaid covers:Fed minutes showing officials split on whether in ... Show more

. 10min 51sec

Apple Commits $30B to Broadcom in Chip Deal, Blue Origin Raises $10B

Market update for July 8, 2026. Check out the Public app for incredible investing tools and to support the show (LINK)Follow us on Instagram (@TheRundownDaily) for bonus content and instant reactions.In today’s episode, Zaid covers:Oil prices ripping higher after Trump says the U ... Show more

. 9min 28sec

Recommended Episodes

The weight-loss drug revolution

Business Daily

Diabetes and obesity drugs like Ozempic, Wegovy and Mounjaro have become famous for helping users shed big amounts of weight. It's a market that could soon be worth more than $100 billion. Two companies dominate this space, Novo Nordisk which makes Ozempic and Eli Lilly, maker of ... Show more

. 17min 28sec

The Big Business Behind Weight Loss Drugs

Chasing Life

It’s become a multibillion-dollar business: weight loss drugs. Demand is high, as is the cost. How did medications like Ozempic, Wegovy, Mounjaro and Zepbound become so popular and so profitable? And what kind of impact might they have on the future of food and healthcare? Dr. Sa ... Show more

. 33min 54sec

How Ozempic Transformed the Way We Look at Obesity

Chasing Life

Ozempic, Wegovy, and Mounjaro, are being called “miracle drugs” with users boasting about their fast results. Dr. Sanjay Gupta takes a deep dive into how they disrupted the entire weight loss industry and changed the conversation about obesity. Learn more about your ad choices. ... Show more

. 23min 47sec

068 | The weight is over: How GLP-1 treatments are reshaping pharma and beyond

Tomorrow – A podcast by Allianz Research

Weight-loss drugs have become a golden formula for pharma growth. In this episode we speak to Sector Advisor Maria Latorre and Senior Economist Michaela Grimm about how GLP-1 treatments like Ozempic and Wegovy are reshaping the industry, and the risks that lie ahead. SHOWNOTES: • ... Show more

. 11min 16sec